Just how sadly misguided is the FDA on aducanumab?
I doubt very much that Biogen paid anyone at the FDA to get an approval on aducanumab with this generous (?) label. But if they had, I doubt that even the execs at Biogen would have asked for this much.
Cheating requires some caution, if you expect to get away with it. And this one goes way past a cautious manipulation of regulatory powers in accomplishing a megablockbuster company goal worth potentially tens of billions of dollars.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.